Indication

Pituitary dwarfism

Pituitary dwarfism, historically termed hyposomatotropic dwarfism or growth hormone deficiency dwarfism, is an endocrine disorder characterized by abnormally short stature resulting from inadequate secretion of growth hormone by the anterior pituitary gland. Read more about Pituitary dwarfism

19 drugs 12 manufacturers

Advertisement

Drugs that treat it

Common Pituitary dwarfism therapies.

Showing 1–9 of 19 drugs

Filter & compare in the drug finder →Opens the drug finder with Pituitary dwarfism preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Pituitary dwarfism.

Pituitary dwarfism, historically termed hyposomatotropic dwarfism or growth hormone deficiency dwarfism, is an endocrine disorder characterized by abnormally short stature resulting from inadequate secretion of growth hormone by the anterior pituitary gland.

Primarily manifesting in infants and children during active skeletal development, it causes significantly diminished linear growth velocity.

Unlike skeletal dysplasias that cause disproportionate limbs, its defining clinical feature is proportionate short stature, frequently accompanied by delayed bone age, delayed dental eruption, and postponed pubertal maturation.

Pathophysiologically, the condition stems from congenital genetic mutations, structural hypothalamic-pituitary malformations, or acquired insults such as intracranial tumors, trauma, or central nervous system irradiation, occurring either as an isolated growth hormone deficiency or as part of combined panhypopituitarism.

Personalize your experience

Follow Pituitary dwarfism and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it